U.S. Human Papillomavirus Testing Market (2025 - 2033) Size, Share & Trends Analysis Report By Application (Cervical Cancer Screening, Vaginal Cancer Screening), By Product, By Technology, By End Use, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Segment Definitions
                        1.2.1. Application
                        1.2.2. Product
                        1.2.3. Technology
                        1.2.4. End Use
                        1.2.5. Regional Scope
                        1.2.6. Estimates and Forecasts Timeline
                    1.3. Research Methodology
                    1.4. Information Procurement
                        1.4.1. Purchased Database
                        1.4.2. GVR’s Internal Database
                        1.4.3. Secondary Sources
                        1.4.4. Primary Research
                        1.4.5. Details of Primary Research
                    1.5. Information or Data Analysis
                        1.5.1. Data Analysis Models
                    1.6. Market Formulation & Validation
                    1.7. Model Details
                    1.8. List of Secondary Sources
                    1.9. List of Primary Sources
                    1.10. Objectives
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                        2.2.1. Application Outlook
                        2.2.2. Product Outlook
                        2.2.3. Technology Outlook
                        2.2.4. End Use Outlook
                        2.2.5. Regional Outlook
                    2.3. Competitive Scenario
Chapter 3. U.S. Human Papillomavirus (HPV) Testing Market Variables, Trends, & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent Market Outlook
                        3.1.2. Related/Ancillary Market Outlook
                    3.2. Market Dynamics
                        3.2.1. Market Driver Analysis
                        3.2.2. Market Restraint Analysis
                    3.3. U.S. Human Papillomavirus (HPV) Testing Market Analysis Tools
                        3.3.1. Industry Analysis - Porter’s Five Forces Analysis
                            3.3.1.1. Supplier Power
                            3.3.1.2. Buyer Power
                            3.3.1.3. Substitution Threat
                            3.3.1.4. Threat of New Entrant
                            3.3.1.5. Competitive Rivalry
                        3.3.2. PESTLE Analysis
                            3.3.2.1. Political Landscape
                            3.3.2.2. Technological Landscape
                            3.3.2.3. Economic Landscape
Chapter 4. U.S. Human Papillomavirus (HPV) Testing Market: Application Estimates & Trend Analysis
                    4.1. Application Segment Dashboard
                    4.2. U.S. Human Papillomavirus (HPV) Testing Market: Application Movement Analysis
                    4.3. U.S. Human Papillomavirus (HPV) Testing Market Size & Trend Analysis, By Application, 2021 to 2033 (USD Million)
                    4.4. Cervical Cancer Screening
                        4.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
                    4.5. Vaginal Cancer Screening
                        4.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
Chapter 5. U.S. Human Papillomavirus (HPV) Testing Market: Product Estimates & Trend Analysis
                    5.1. Product Segment Dashboard
                    5.2. U.S. Human Papillomavirus (HPV) Testing Market: Product Movement Analysis
                    5.3. U.S. Human Papillomavirus (HPV) Testing Market Size & Trend Analysis, By Product, 2021 to 2033 (USD Million)
                    5.4. Instruments
                        5.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
                    5.5. Consumables
                        5.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
                    5.6. Services
                        5.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
Chapter 6. U.S. Human Papillomavirus (HPV) Testing Market: Technology Estimates & Trend Analysis
                    6.1. Technology Segment Dashboard
                    6.2. U.S. Human Papillomavirus (HPV) Testing Market: Technology Movement Analysis
                    6.3. U.S. Human Papillomavirus (HPV) Testing Market Size & Trend Analysis, By Technology, 2021 to 2033 (USD Million)
                    6.4. PCR
                        6.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
                    6.5. Immunodiagnostics
                        6.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
                    6.6. Others
                        6.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
Chapter 7. U.S. Human Papillomavirus (HPV) Testing Market: End Use Estimates & Trend Analysis
                    7.1. End Use Segment Dashboard
                    7.2. U.S. Human Papillomavirus (HPV) Testing Market: End Use Movement Analysis
                    7.3. U.S. Human Papillomavirus (HPV) Testing Market Size & Trend Analysis, By End Use, 2021 to 2033 (USD Million)
                    7.4. Hospitals & Clinics
                        7.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
                    7.5. Laboratories
                        7.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
                    7.6. Others
                        7.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
Chapter 8. Competitive Landscape
                    8.1. Recent Developments & Impact Analysis, By Key Market Participants
                    8.2. Company/ Competition Categorization
                    8.3. Vendor Landscape
                        8.3.1. Key Company Heat Map Analysis, 2024
                    8.4. Company Profiles
                        8.4.1. Abbott
                            8.4.1.1. Company Overview
                            8.4.1.2. Financial Performance
                            8.4.1.3. Product Benchmarking
                            8.4.1.4. Strategic Initiatives
                        8.4.2. Biomedical Diagnostics
                            8.4.2.1. Company Overview
                            8.4.2.2. Financial Performance
                            8.4.2.3. Product Benchmarking
                            8.4.2.4. Strategic Initiatives
                        8.4.3. bioMerieux
                            8.4.3.1. Company Overview
                            8.4.3.2. Financial Performance
                            8.4.3.3. Product Benchmarking
                            8.4.3.4. Strategic Initiatives
                        8.4.4. Bio-Rad Laboratories, Inc.
                            8.4.4.1. Company Overview
                            8.4.4.2. Financial Performance
                            8.4.4.3. Product Benchmarking
                            8.4.4.4. Strategic Initiatives
                        8.4.5. Fujirebio
                            8.4.5.1. Company Overview
                            8.4.5.2. Financial Performance
                            8.4.5.3. Product Benchmarking
                            8.4.5.4. Strategic Initiatives
                        8.4.6. Oncolab
                            8.4.6.1. Company Overview
                            8.4.6.2. Financial Performance
                            8.4.6.3. Product Benchmarking
                            8.4.6.4. Strategic Initiatives
                        8.4.7. Hologic, Inc.
                            8.4.7.1. Company Overview
                            8.4.7.2. Financial Performance
                            8.4.7.3. Product Benchmarking
                            8.4.7.4. Strategic Initiatives
                        8.4.8. Qiagen
                            8.4.8.1. Company Overview
                            8.4.8.2. Financial Performance
                            8.4.8.3. Product Benchmarking
                            8.4.8.4. Strategic Initiatives
                        8.4.9. F. Hoffmann-La Roche Ltd
                            8.4.9.1. Company Overview
                            8.4.9.2. Financial Performance
                            8.4.9.3. Product Benchmarking
                            8.4.9.4. Strategic Initiatives
                        8.4.10. Siemens Healthineers AG
                            8.4.10.1. Company Overview
                            8.4.10.2. Financial Performance
                            8.4.10.3. Product Benchmarking
                            8.4.10.4. Strategic Initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 U.S. Human Papillomavirus (HPV) Testing Market, by Application, 2021 - 2033 (USD Million)
Table 4 U.S. Human Papillomavirus (HPV) Testing Market, by Product, 2021 - 2033 (USD Million)
Table 5 U.S. Human Papillomavirus (HPV) Testing Market, by Technology, 2021 - 2033 (USD Million)
Table 6 U.S. Human Papillomavirus (HPV) Testing Market, by End Use, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Market Research Process
Fig. 2 Data Triangulation Techniques
Fig. 3 Primary Research Pattern
Fig. 4 Primary Interviews
Fig. 5 Market Research Approaches
Fig. 6 Value-Chain-Based Sizing & Forecasting
Fig. 7 QFD Modeling for Market Share Assessment
Fig. 8 Market Formulation & Validation
Fig. 9 U.S. Human Papillomavirus (HPV) Testing Market: Market Outlook
Fig. 10 Human Papillomavirus (HPV) Testing Competitive Insights
Fig. 11 Parent Market Outlook
Fig. 12 Related/Ancillary Market Outlook
Fig. 13 Penetration and Growth Prospect Mapping
Fig. 14 Industry Value Chain Analysis
Fig. 15 U.S. Human Papillomavirus (HPV) Testing Market Driver Impact
Fig. 16 U.S. Human Papillomavirus (HPV) Testing Market Restraint Impact
Fig. 17 U.S. Human Papillomavirus (HPV) Testing Market Strategic Initiatives Analysis
Fig. 18 U.S. Human Papillomavirus (HPV) Testing Market: Application Movement Analysis
Fig. 19 U.S. Human Papillomavirus (HPV) Testing Market: Application Outlook and Key Takeaways
Fig. 20 Cervical Cancer Screening Market Estimates and Forecast, 2021 - 2033
Fig. 21 Vaginal Cancer Screening Market Estimates and Forecast, 2021 - 2033
Fig. 22 U.S. Human Papillomavirus (HPV) Testing Market: Product Movement Analysis
Fig. 23 U.S. Human Papillomavirus (HPV) Testing Market: Product Outlook and Key Takeaways
Fig. 24 Instruments Market Estimates and Forecast, 2021 - 2033
Fig. 25 Consumables Market Estimates and Forecast, 2021 - 2033
Fig. 26 Services Market Estimates and Forecast, 2021 - 2033
Fig. 27 U.S. Human Papillomavirus (HPV) Testing Market: Technology Movement Analysis
Fig. 28 U.S. Human Papillomavirus (HPV) Testing Market: Technology Outlook and Key Takeaways
Fig. 29 PCR Market, 2021 - 2033 (USD Million)
Fig. 30 Immunodiagnostics Market, 2021 - 2033 (USD Million)
Fig. 31 Others Market, 2021 - 2033 (USD Million)
Fig. 32 U.S. Human Papillomavirus (HPV) Testing Market: End Use Movement Analysis
Fig. 33 U.S. Human Papillomavirus (HPV) Testing Market: End Use Outlook and Key Takeaways
Fig. 34 Hospitals & Clinics Market, 2021 - 2033 (USD Million)
Fig. 35 Laboratories Market, 2021 - 2033 (USD Million)
Fig. 36 Others Market, 2021 - 2033 (USD Million)
Fig. 40 U.S. Market Estimates and Forecasts, 2021 - 2033